Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd has announced its half-year financial results will be released on August 22, 2024, with an investor webcast to follow on August 23. The Melbourne-based biopharmaceutical company specializes in radiopharmaceuticals for oncology and rare diseases and has operations across the globe. Their lead product, Illuccix, has received approval in the US, Australia, and Canada.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
